Select status:
Sort by:
Filter by last updated date

Please enter a valid month/year e.g. 01/2015

Pick a date between March 2000 and October 2021

Filter by area of interest
Filter by type
Showing 1 to 10 of 564
Title Reference number Published Last updated
Tofacitinib for treating juvenile idiopathic arthritis Reference number:TA735 TA00735 Published:20 October 2021 20211020 Last updated:20 October 2021 20211020
Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy Reference number:TA736 TA00736 Published:20 October 2021 20211020 Last updated:20 October 2021 20211020
Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer Reference number:TA737 TA00737 Published:20 October 2021 20211020 Last updated:20 October 2021 20211020
Berotralstat for preventing recurrent attacks of hereditary angioedema Reference number:TA738 TA00738 Published:20 October 2021 20211020 Last updated:20 October 2021 20211020
Secukinumab for treating moderate to severe plaque psoriasis in children and young people Reference number:TA734 TA00734 Published:07 October 2021 20211007 Last updated:07 October 2021 20211007
Baloxavir marboxil for treating acute uncomplicated influenza (terminated appraisal) Reference number:TA732 TA00732 Published:06 October 2021 20211006 Last updated:06 October 2021 20211006
Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia Reference number:TA733 TA00733 Published:06 October 2021 20211006 Last updated:06 October 2021 20211006
Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours (terminated appraisal) Reference number:TA730 TA00730 Published:29 September 2021 20210929 Last updated:29 September 2021 20210929
Vericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal) Reference number:TA731 TA00731 Published:29 September 2021 20210929 Last updated:29 September 2021 20210929
Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) Reference number:TA726 TA00726 Published:22 September 2021 20210922 Last updated:22 September 2021 20210922